CDX2 and cancer: Mutations in other genes of the WNT/β-catenin pathway were more prevalent in the CDX2-suppressed group, with the most significant differences observed in RNF43, which was mutated in 81.3% of the cases in this group versus 3.9% of the cases in non-CDX2-suppressed cancers (Fisher’s exact test p < 0.0001, Figure 1), and in atypical cadherin FAT4, which was mutated in 75% of the cases in the CDX2-suppressed group versus 18.2% of the cases in non-CDX2-suppressed cancers (Fisher’s exact test p < 0.0001, Figure 17).